← Leaderboards
Hongkang Zhang
Quiver Bioscience Inc.
$1,927,486
Attributed
$3,854,972
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,854,972 · 3
By mechanism
R44$3,854,972 · 3
Top collaborators
- Owen B. Mcmanus4 shared
- Fabricio Simao1 shared
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroIn VivoToxic EffectVoltageElectrophysiology (Science)RattusSide EffectTechnologyNeuronsOpticsDrug KineticsDesignDoseAntisense OligonucleotidesAnimal ModelEffective TherapyPainNervous System DisorderMedicalCellsModalityNeuronal ExcitabilityNociceptionAfferent Neurons
Grant awards (5)
Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity$862,420
R44 · FY2025 · NS
Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets$995,305
R44 · FY2022 · CA · contact PI
Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets$1,000,001
R44 · FY2021 · CA · contact PI
A phenotypic screen for osteoarthritic pain therapeutics using all-optical electrophysiology.$696,518
R44 · FY2021 · AR · contact PI
Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets$300,728
R44 · FY2020 · CA · contact PI